Latest Psoriasis Stories
European Dermatologists Indicate that Fewer than Half of Their Severe Patients are being Treated with a Biologic, According to Findings from Decision Resources Group BURLINGTON, Mass., May
COVA322 is First of Covagen's Bispecific FynomAbs to Enter Clinical Trials ZURICH-SCHLIEREN, Switzerland, May 5, 2014 /PRNewswire/ --
Patented French maritime pine bark extract shown to significantly reduce the most common signs of psoriasis by reducing inflammation, increasing skin hydration and fighting free radicals HOBOKEN,
Expert Opinion Indicates That Humira and Cimzia Have the Best Clinical Profiles of Key Marketed Therapies, According to Findings from Decision Resources Group BURLINGTON, Mass., April 30, 2014
Frost & Sullivan: Comparative efficacy data critical for higher uptake since psoriasis is not considered a life-threatening condition MOUNTAIN VIEW, Calif., April 30, 2014 /PRNewswire/ -- The
ReportsnReports.com offers Therapeutic Class Overview: Psoriasis – Plaque Psoriasis & Psoriatic Arthritis: Novel Oral drugs and Biologics to Change Future Treatment Paradigm market research
CHARLESTON, S.C., April 16, 2014 /PRNewswire/ -- Innocutis, a specialty pharmaceutical company in Dermatologic and Podiatric specialties, is pleased to announce that Nuvail [poly-ureaurethane,
MarketOptimizer.org offers “Xeljanz (Psoriasis) – Forecast and Market Analysis to 2022” research report in its store.
FORT WORTH, Texas, April 14, 2014 /PRNewswire/ -- ReCept announces that it is among a select group of specialty pharmacies selected by Celgene to distribute Otezla® (apremilast), a new
- The act of sweetening by admixture of some saccharine substance.